{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:09:51Z","timestamp":1785816591371,"version":"3.56.0"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Prostate-specific antigen (PSA) testing is a key tool in the early detection and monitoring of prostate cancer. While venous blood is the standard matrix for PSA measurement, capillary blood sampling represents a minimally invasive alternative that may facilitate broader access to testing. This prospective study investigated the agreement between capillary and venous measurements of total and free PSA in 224 male patients at ALTA Klinik Bielefeld, Germany. Blood samples were collected between April and June 2021 and analyzed using electrochemiluminescence immunoassays. The results showed strong correlations between capillary and venous samples for both total PSA (r\u2009=\u20090.99, p\u2009&lt;\u20090.01) and free PSA (r\u2009=\u20090.98, p\u2009&lt;\u20090.01). Mean differences were 0.35 ng\/mL for total PSA and 0.27 ng\/mL for free PSA. Bland-Altman analysis demonstrated good agreement between both methods, with most values falling within the 95% confidence limits. These findings suggest that capillary blood sampling may be a suitable alternative to venous blood for PSA testing, particularly within the clinically relevant range up to 10 ng\/mL. Furthermore, the feasibility of determining both total and free PSA in capillary samples allows calculation of the fPSA\/tPSA ratio, which may improve diagnostic specificity in early prostate cancer detection.<\/jats:p>","DOI":"10.1371\/journal.pone.0335448","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T17:33:10Z","timestamp":1761759190000},"page":"e0335448","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of PSA Values from capillary dried blood spot analysis and venous serum samples"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6624-0372","authenticated-orcid":true,"given":"Lucas","family":"Engelage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3043-0672","authenticated-orcid":true,"given":"Niklas","family":"Behnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6281-6498","authenticated-orcid":true,"given":"Agron","family":"Lumiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Tamalunas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7895-7070","authenticated-orcid":true,"given":"Alexander","family":"Buchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Sroka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"issue":"3","key":"pone.0335448.ref001","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"19","key":"pone.0335448.ref002","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1001\/jama.279.19.1542","article-title":"Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial","volume":"279","author":"WJ Catalona","year":"1998","journal-title":"JAMA"},{"issue":"13","key":"pone.0335448.ref003","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010249","article-title":"Value of free\/total prostate-specific antigen (f\/t PSA) ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10\u200ang\/mL: A meta-analysis","volume":"97","author":"Y Huang","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"pone.0335448.ref004","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1023\/A:1007116807012","article-title":"The clinical value of the ratio of free prostate specific antigen to total prostate specific antigen","volume":"31","author":"I Dalva","year":"1999","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"pone.0335448.ref005","first-page":"539","article-title":"Time-resolved-fluoroimmunoassay for the determination of prostate-specific-antigen in capillary-blood spotted on filter paper and its clinical significance in prostate cancer patients","volume":"42","author":"S Ito","year":"1994","journal-title":"Rinsho Byori"},{"issue":"9","key":"pone.0335448.ref006","first-page":"1321","article-title":"Compliance of blood sampling procedures with the CLSI H3-A6 guidelines: An observational study by the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) working group for the preanalytical phase (WG-PRE)","volume":"53","author":"A-M Simundic","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"pone.0335448.ref007","volume-title":"WHO guidelines on drawing blood: best practices in phlebotomy","author":"World Health Organization","year":"2010"},{"key":"pone.0335448.ref008","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-1-4939-7614-0_16","article-title":"Capillary Blood Sampling from the Finger","volume":"1735","author":"K Rooney","year":"2018","journal-title":"Methods Mol Biol"},{"issue":"3","key":"pone.0335448.ref009","first-page":"69","article-title":"Statistics corner: A guide to appropriate use of correlation coefficient in medical research","volume":"24","author":"MM Mukaka","year":"2012","journal-title":"Malawi Med J"},{"issue":"1","key":"pone.0335448.ref010","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","article-title":"A power primer","volume":"112","author":"J Cohen","year":"1992","journal-title":"Psychol Bull"},{"issue":"8476","key":"pone.0335448.ref011","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement","volume":"1","author":"JM Bland","year":"1986","journal-title":"Lancet Lond Engl"},{"issue":"12","key":"pone.0335448.ref012","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1515\/cclm-2023-0272","article-title":"Self-sampling of blood using a topper and pediatric tubes; a prospective feasibility study for PSA analysis using 120 prostate cancer patients","volume":"61","author":"N van den Brink","year":"2023","journal-title":"Clin Chem Lab Med"},{"key":"pone.0335448.ref013","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12894-015-0105-7","article-title":"Evaluation of a rapid quantitative determination method of PSA concentration with gold immunochromatographic strips","volume":"15","author":"CC Wu","year":"2015","journal-title":"BMC Urol"},{"key":"pone.0335448.ref014","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/(SICI)1097-0045(1996)7+<3::AID-PROS1>3.0.CO;2-T","article-title":"Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values","volume":"7","author":"A Semjonow","year":"1996","journal-title":"Prostate Suppl"},{"key":"pone.0335448.ref015","unstructured":"European Medicines Agency. Guideline on bioanalytical method validation. EMA\/CHMP\/EWP\/192217\/2009 Rev.1 Corr.2. 2011."},{"issue":"2","key":"pone.0335448.ref016","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s12668-017-0465-4","article-title":"Prostate-specific antigen: a review of assay techniques, variability and their clinical implications","volume":"8","author":"N Gill","year":"2018","journal-title":"BioNanoScience"},{"issue":"1","key":"pone.0335448.ref017","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1373\/clinchem.2005.059170","article-title":"Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update","volume":"52","author":"C Stephan","year":"2006","journal-title":"Clin Chem"},{"issue":"6","key":"pone.0335448.ref018","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/S0022-5347(01)64711-6","article-title":"Biological variation of prostate specific antigen levels in serum: an evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients","volume":"157","author":"RG Nixon","year":"1997","journal-title":"J Urol"},{"issue":"8","key":"pone.0335448.ref019","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1373\/clinchem.2004.046086","article-title":"Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice","volume":"51","author":"G S\u00f6l\u00e9tormos","year":"2005","journal-title":"Clin Chem"},{"issue":"12","key":"pone.0335448.ref020","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw165","article-title":"Repeat prostate-specific antigen tests before prostate biopsy decisions","volume":"108","author":"T Nordstr\u00f6m","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"pone.0335448.ref021","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter","volume":"350","author":"IM Thompson","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0335448.ref022","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s12668-017-0465-4","article-title":"Prostate-Specific Antigen: A Review of Assay Techniques, Variability and Their Clinical Implications","volume":"8","author":"N Gill","year":"2018","journal-title":"BioNanoScience"},{"issue":"2","key":"pone.0335448.ref023","first-page":"173","article-title":"Second Stanford Conference on International Standardization of Prostate-Specific Antigen Immunoassays:","volume":"2","author":"TA Stamey","year":"1995","journal-title":"September 1 and"},{"issue":"2","key":"pone.0335448.ref024","doi-asserted-by":"crossref","first-page":"261","DOI":"10.21037\/tau-23-29","article-title":"Consistency and diagnostic accuracy of 4 assays in the detection of the total and free prostate-specific antigen","volume":"12","author":"L Deng","year":"2023","journal-title":"Transl Androl Urol"},{"issue":"1","key":"pone.0335448.ref025","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1373\/clinchem.2005.059170","article-title":"Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update","volume":"52","author":"C Stephan","year":"2006","journal-title":"Clin Chem"},{"key":"pone.0335448.ref026","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1097\/01.ju.0000091100.83725.51","article-title":"Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens","volume":"170","author":"JA Eastham","year":"2003","journal-title":"J Urol"},{"issue":"15","key":"pone.0335448.ref027","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1056\/NEJM198710083171501","article-title":"Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate","volume":"317","author":"TA Stamey","year":"1987","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0335448.ref028","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.eururo.2007.11.064","article-title":"Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study","volume":"53","author":"DJ Rosario","year":"2008","journal-title":"Eur Urol"},{"issue":"1","key":"pone.0335448.ref029","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bju.14197","article-title":"Repeat prostate-specific antigen (PSA) test before prostate biopsy: a 20% decrease in PSA values is associated with a reduced risk of cancer and particularly of high-grade cancer","volume":"122","author":"C De Nunzio","year":"2018","journal-title":"BJU Int"},{"issue":"5","key":"pone.0335448.ref030","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1080\/10408363.2017.1343796","article-title":"Capillary blood for point-of-care testing","volume":"54","author":"R Tang","year":"2017","journal-title":"Crit Rev Clin Lab Sci"},{"key":"pone.0335448.ref031","author":"Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF","year":"2021"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0335448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T17:33:14Z","timestamp":1761759194000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0335448"}},"subtitle":[],"editor":[{"given":"Rajeevan","family":"Selvaratnam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":31,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0335448","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]}}}